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Background: Cell-targeting peptides or proteins are appealing tools in nanomedicine and 
innovative medicines because they increase the local drug concentration and reduce potential 
side effects. CXC chemokine receptor 4 (CXCR4) is a cell surface marker associated with 
several severe human pathologies, including colorectal cancer, for which intracellular targeting 
agents are currently missing.
Results: Four different peptides that bind CXCR4 were tested for their ability to internalize a 
green fluorescent protein-based reporter nanoparticle into CXCR4+ cells. Among them, only the 
18 mer peptide T22, an engineered segment derivative of polyphemusin II from the horseshoe 
crab, efficiently penetrated target cells via a rapid, receptor-specific endosomal route. This 
resulted in accumulation of the reporter nanoparticle in a fully fluorescent and stable form in 
the perinuclear region of the target cells, without toxicity either in cell culture or in an in vivo 
model of metastatic colorectal cancer.
Conclusion: Given the urgent demand for targeting agents in the research, diagnosis, and 
treatment of CXCR4-linked diseases, including colorectal cancer and human immunodeficiency 
virus infection, T22 appears to be a promising tag for the intracellular delivery of protein drugs, 
nanoparticles, and imaging agents.
Keywords: peptide tag, CXCR4, intracellular targeting, self-assembling, nanoparticles, 
colorectal cancer
Introduction
Unlike conventional therapies, nanomedicine and innovative medicines in general 
pursue targeted intracellular delivery of chemotherapy and imaging agents, and 
are expected to result in significantly lower effective therapeutic doses, production 
costs, and toxicity.1 Cell-penetrating peptides offer a broad potential for efficient 
internalization of attached cargo because of their affinity for and associated abil-
ity to cross cell membranes.2,3 However, because these activities are not dependent 
on specific cell surface receptors, appropriate cell targeting and biodistribution 
of therapeutic complexes cannot be achieved using cell-penetrating peptides. The 
discovery of disease-linked cell surface markers enables subsequent identification 
of specific ligands for receptor-mediated endocytosis. These entities should be 
capable of driving the uptake of large macromolecular complexes such as nano-
particles, which are useful in a therapeutic context as drug carriers and stabilizers. 
The CXC chemokine receptor 4 (CXCR4) plays a role in inflammation, autoim-
munity, ischemia, and stem cell mobilization.4 In addition, CXCR4 is a coreceptor 
for the human immunodeficiency virus (HIV)5 and an important stem cell marker 
in several common human cancers,6,7 including metastatic colorectal cancer.8,9 
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Therefore, developing new therapeutic agents targeted to 
CXCR4 is a recognized priority in emerging medicines,4 
but because CXCR4 ligands remain poorly studied and 
peptides suitable for CXCR4-mediated endocytosis are 
not available, intracellular targeting to CXCR4+ cells is 
still not feasible. In the present study, we describe peptide 
T22, a known antagonist of CXCR4, that binds to and 
penetrates CXCR4+ cells efficiently via CXCR4-specific 
endocytosis. T22 is an engineered version polyphemusin 
II peptide from the horseshoe crab, in which three sub-
stitutions at residues Tyr5, Lys7, and Tyr12 dramatically 
increase the natural affinity of this peptide for CXCR4.10,11 
When fused to a self-assembling green fluorescent protein 
(GFP)-based building block, T22 promotes fast perinuclear 
accumulation of stable and highly fluorescent nanoparticles 
without cytotoxicity, both in cell culture and in vivo. Thus, 
we propose T22 as a novel cell-targeting peptide suitable 
for functionalization of nanoparticles and appropriate for 
intracellular delivery in CXCR4-associated medicines.
Materials and methods
Protein design, production, purification, 
and characterization
Four chimeric genes were designed inhouse and provided 
by Geneart (Regensburg, Germany). Using NdeI/HindIII 
restriction sites, these genes were introduced into pET22b 
(Novagen 69744-3). All the encoded proteins were produced 
in Escherichia coli Origami B (BL21, OmpT-, Lon-, TrxB-, 
Gor-, Novagen) overnight at 20°C upon addition of 0.1 mM 
isopropyl-β-D-thiogalactopyronaside. Bacterial cells were 
then centrifuged for 45 minutes (5000 g at 4°C) and resus-
pended in Tris buffer (Tris 20 mM, pH 8.0, NaCl 500 mM, 
imidazole 10 mM) in the presence of ethylenediamine 
tetra-acetic acid-free protease inhibitor (Complete EDTA-
Free, Roche, Basel, Switzerland). The cells were disrupted 
at 1100 psi in a French press (Thermo FA-078A) and their 
proteins were purified by 6 × His tag affinity chromatography 
using HiTrap Chelating HP 1 mL (GE Healthcare, Piscataway, 
NJ) columns with an AKTA purifier FPLC (GE Healthcare). 
Elution was achieved by a linear gradient of Tris 20 mM, 
pH 8.0, 500 mM NaCl, and 500 mM imidazole, and the pro-
teins eluted were finally dialyzed against phosphate-buffered 
solution (140 mM NaCl, 7.5 mM Na
2
HPO
4
, 2.5 mM NaH
2
PO
4
) 
plus 10% glycerol, pH 7.4, against carbonate buffer (166 mM 
NaCO
3
H + 333 mM NaCl, pH 7.4) or against Tris 20 mM + 
NaCl 500 mM, pH 7.5. The integrity of the resulting proteins 
was checked by both mass spectrometry and N-terminal 
sequencing using the Edman degradation method, and 
their amounts were determined by Bradford’s assay.12 
In addition, all products were analyzed by Coomassie-stained 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
and anti-His Western blot analysis. The fusion proteins 
were named according to N→C modular organization by 
the name of the CXCR4 ligand, followed by GFP and H6 
(hexahistidine tail).
TEM, fluorescence determination,  
and dynamic light scattering
Purified proteins were diluted to 0.2 mg/mL and contrasted 
by evaporation of 1 nm platinum layer in carbon-coated grids. 
Samples were visualized in a Hitachi H-7000 transmission 
electron microscope. Fluorescence of the nanoparticles was 
determined in a Cary Eclipse fluorescence spectrophotometer 
(Varian Inc, Palo Alto, CA) at 510 nm using an excitation 
wavelength of 450 nm. The volume and size distribution of 
the nanoparticles was determined by dynamic light scattering 
at 633 nm (Zetasizer Nano ZS, Malvern Instruments Limited, 
Malvern, Worcestershire, UK).
Protein stability analysis
Stability of the T22-GFP-H6 (amino terminus of a His-tagged 
enhanced GFP) was analyzed in triplicate in human serum 
(S2257-5ML, Sigma, St Louis, MO) at 37°C, with agitation 
and at a final concentration of 0.23 µg/µL. Fluorescence 
was determined as described earlier, and the integrity of 
the T22-GFP-H6 was confirmed by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis and further Western 
blotting. Nitrocellulose membranes were developed using 
an anti-GFP rabbit polyclonal serum.
Cell culture and confocal laser scanning 
microscopy
The cells were cultured in modified Eagle’s medium (Gibco, 
Rockville, MD) supplemented with 10% fetal calf serum 
(Gibco), and incubated at 37°C and 5% CO
2
 in a humidified 
atmosphere. Nanoparticles were added to the cell culture in 
the presence of Optipro medium (Gibco) 20 hours before 
confocal analysis, except for the time-course and internaliza-
tion studies in the presence of serum (complete medium). For 
confocal analysis, the cells were grown on MatTek culture 
dishes (MatTek Corporation, Ashland, MA). The nuclei were 
labeled with 0.2 µg/mL Hoechst 33342 (Molecular Probes, 
Eugene, OR) and the plasma membranes with 2.5 µg/mL 
CellMaskTM Deep Red (Molecular Probes) for 10 minutes 
in the dark. The cells were washed in phosphate-buffered 
saline (Sigma-Aldrich Chemie GmbH, Steinheim, Germany). 
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Live cells were recorded by TCS-SP5 confocal laser scanning 
microscopy (Leica Microsystems, Heidelberg, Germany) 
using a Plan Apo 63 × /1.4 (oil HC × PL APO lambda blue) 
objective as described elsewhere.13 To determine particle 
localization inside the cell, stacks of 10–20 sections for 
every 0.5 µm of cell thickness were collected and three-
dimensional models were generated using Imaris version 
6.1.0 software (Bitplane, Zürich, Switzerland) as reported 
previously.14 Cell samples were analyzed after treatment 
with 1 mg/mL trypsin (Gibco) for 15 minutes on a FACS-
Canto system (Becton Dickinson, Franklin Lakes, NJ) using 
a 15 mW air-cooled argon ion laser at 488 nm excitation. 
Fluorescence emission was measured with a D detector 
(530/30 nm band pass filter). Cell viability was determined 
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay as described elsewhere.15 An HeLa 
cell line was obtained from the American Type Culture 
Collection (reference CCL-2, Manassas, VA) and SW1417 
was a generous gift from Xavier Mayol (Institut Municipal 
D’Investigacio Médica, Barcelona, Spain).16
Molecular modeling
Protein homology models were generated using Modeller, 
Phyre, and Swiss-PdbViewer as reported earlier.17 Also, 
 different Haddock models were obtained, in which the bind-
ing residues were established using crystallographic data 
from multimeric forms of GFP (1GFL, 1JC0, 3GJ2, 2QLE, 
1EMC) and the higher interaction energy solutions resulting 
from protein-protein docking calculation.
Biodistribution analysis
Five-week-old female Swiss nu/nu mice, weighing 18–20 g 
(Charles River, France) maintained in specific pathogen-free 
conditions, were used for the in vivo experiments. All pro-
cedures were approved by the Hospital de Sant Pau animal 
ethics committee. To generate a metastatic colorectal cancer 
model, the mice were injected with 2 million SW-1417 cells 
via the cecal wall, using an orthotopic cell microinjection 
technique.18 Two months after microinjection, when local 
tumor and metastases had appeared, each experimental 
animal received a single intravenous bolus of T22-GFP-H6 
nanoparticles resuspended in a 20 mM Tris, 500 mM NaCl, 
pH 7.4 buffer, at a dose of 20 µg (n = 3 mice) or 500 µg 
(n = 3 mice). Control animals received a single bolus of 
empty buffer. After euthanizing the mice at 5, 24, or 48 hours 
post-administration, we measured ex vivo the amount of 
nanoparticles in normal and tumor-bearing organs from the 
experimental and control mice, quantifying the fluorescence 
emitted by each organ. To this end, primary tumors, organs 
bearing metastatic foci, and several samples of normal tissue 
(kidney, liver, lung, heart) were obtained at necropsy, cut into 
slices, and placed in separate wells to detect the emitted signal 
using IVIS® Spectrum equipment (Xenogen Biosciences, 
Waltham, MA). The amount of nanoparticles distributed 
in each tissue was calculated as the increased fluorescent 
(FLI) ratio. The fluorescence signal was first digitalized, 
displayed as a pseudocolor overlay, and expressed as radi-
ant efficiency. Thereafter, the FLI ratio was calculated for 
each organ, dose, and post-treatment time, dividing the FLI 
signal from the nanoparticle-treated mice by the FLI signal 
from the control mice. Finally, all organs were collected and 
fixed with 4% formaldehyde in phosphate-buffered solution 
for 24 hours, and then embedded in paraffin for histological 
and immunohistochemical evaluation.
Immunohistochemistry
Sections of normal and tumor tissues 4 µm thick were stained 
with hematoxylin and eosin. The sections were examined 
histopathologically to analyze the primary tumor and to 
search for metastatic foci in organs with no macroscopic 
metastases. Paraffin-embedded tissue sections were depar-
affinized, rehydrated, and washed in phosphate-buffered 
solution with Tween-20. Antigen retrieval was performed 
using citrate buffer at 120°C. After quenching peroxidase 
activity by incubating the slides in 3% H
2
O
2
 for 10 minutes, 
the slides were washed in phosphate-buffered solution with 
Tween-20. The slides were incubated for 30 minutes with the 
primary antibody against CXCR4 (1:20, Biotrend, Destin, 
FL) to detect expression of this receptor in normal tissue 
and tumor tissue. A primary anti-His antibody (1:1000; 
Abcam, Cambridge, UK) was used to detect nanoparticle 
accumulation and localization in normal and tumor  (primary 
or metastatic) tissue. After incubation, the samples were 
washed in phosphate-buffered solution with Tween-20 
and incubated with the biotinylated secondary antibody 
for 30 minutes at room temperature. Finally, the sections 
were counterstained with hematoxylin and mounted using 
DPX mounting medium. Representative pictures were taken 
using Cell^B software (Olympus Soft Imaging) at 200× and 
1000× magnifications.
Statistical analysis
The data were evaluated by one-way Anova analysis of 
variance with a confidence level of 99.9% (P , 0.001). 
Dose-response plots were analyzed by nonlinear regression 
analysis using SigmaPlot 10. The data for both the HeLa and 
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SW1417 cells fitted into a double rectangular hyperbolic 
function, with a significance level of 99.9% (P , 0.001). 
All data were expressed as the mean ± standard error of 
the mean.
Results
Screening CXCR4 peptidic ligands  
for cell-targeted internalization
To identify peptides suitable for use as tags for CXCR4-
mediated cell internalization of large macromolecular com-
plexes, four known molecular ligands of CXCR4, namely 
peptide T22, the protein domains CXCL2 and vCCL2, and 
V1, an amino-terminal peptide of vCCL2 (Figure 1A), were 
tested for their ability to promote receptor-mediated delivery 
of attached macromolecular entities into CXCR4-expressing 
cells. All these protein segments were fused to GFP-H6. 
This fluorescent protein, when containing cationic peptides 
at its amino terminus, shows a tendency to self-assemble 
as regular-sized nanoparticles, presumably by electrostatic 
interaction between monomers.13 Because of their emission 
of fluorescence, these nanoparticles are very convenient 
reporters for use in internalization and trafficking studies.14 
Four equivalent modular constructs differing only by the 
CXCR4 ligand (Figure 1B) were designed according to this 
strategy, produced in bacteria, and purified as full-length 
forms of the expected molecular mass and N-terminal 
amino acid sequence (Figure 2). Their reactivity in anti-His 
Western blot analysis indicated protein integrity also at the 
C-terminus. Only vCCL12 showed partial degradation at the 
N-terminus, but retained most of the expected molecular mass 
(Figure 2). This proteolytic instability was observed under 
all tested production conditions and in several E. coli strains 
tested as hosts (data not shown). In addition, the single major 
peak in mass spectroscopy and the unambiguous N-terminal 
sequence, coincident with a few dominant bands in Western 
blot analysis, indicated the existence of conformational 
isoforms of vCCL12.
When these proteins were added to the culture medium, 
HeLa (CXCR4+) cells exposed to T22-GFP-H6 were ten-
fold more fluorescent than those exposed to V1, CXCL12, 
and vCCL2 fusion (Figure 3). Interestingly, cell uptake of 
CXCL12 and V1 has been reported previously,19,20 but the 
excellent performance of T22 was completely unexpected 
because its ability to internalize cells has not been previously 
suggested or described, despite its well known properties as 
an CXCR4 antagonist.21 As expected, the untagged parental 
GFP-H6 building block did not label the cells.
CXCR4-dependent cell uptake  
of T22-empowered constructs
The high cell penetrability of T22-activated GFP was 
 further confirmed by confocal microscopy of treated HeLa 
cell cultures (Figure 4A). In full agreement with data from 
Figure 3, no penetration of GFP-H6 was observed, while 
some uptake of CXCL12 and to a minor extent some vCCL2-
GFP-H6 was seen. V1-GFP-H6 was observed inside cells as 
low in abundance and poorly fluorescent punctuate entities. 
 Three-dimensional reconstructions of individual cells exposed 
to T22-GFP-H6 indicated perinuclear localization of fluo-
rescence in the form of nanoparticles (Figure 4B). Discrete 
yellow merging signals (green particles incorporated into 
red membranous vesicles) were observed close to the plasma 
membrane (Figure 4C), indicative of uptake by endosomes. 
The finding of nanoparticles within the endosomes was fully 
confirmed by three-dimensional confocal reconstructions as 
yellow spots, some of them fully internalized in the cytoplasm 
and separate from the plasma membrane (Figure 4C, inset). 
However, the relative low proportion of yellow signals and 
N
A B
L eGFP CH6
GGSSRSS KHHHHHH
T22-GFP-H6T22 RRWCYRKCYKGYCYRKCR
KPVSLSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPKLKWIQEYLEKALN
LGASWHRPDKCCLGYQKRPLP
LGASWHRPDKCCLGYQKRPLPQVLLSSWYPTSQLCSKPGVIFLTKRGRQVCADKDWVKKLMQQLPVTA
V1
vCCL2
CXCL12
V1-GFP-H6 vCCL2-GFP-H6 CXCL12-GFP-H6
Figure 1 Features of protein constructs containing peptidic CXCR4 ligands. (A) Schematic representation of CXCR4-binding constructs indicating their modular composition. 
A linker (yellow box) commonly used in phage display was inserted between the protein ligand (L, blue) and eGFP (green). The amino acid sequences of the four ligands are 
shown. In all cases, an additional amino terminal methionine, derived from the cloning strategy adapted to Escherichia coli was expected. (B) Predicted structure of the different 
GFP-derived constructs. The color code of panel A is maintained here for both ligand- (blue) and H6- (red) overhanging ends.
Abbreviation: GFP, green fluorescent protein.
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rapid accumulation of nanoparticles close to the nuclear 
region through fast cytoplasmic trafficking (Figure 4D) were 
indicative of early endosomal escape. This was probably 
promoted by the accompanying hexahistidine tag, that has 
powerful endosomolytic properties,22 inducing early endo-
somal escape in related protein-only nanoparticles.14 Ten 
minutes after exposure to these T22 constructs, the uptake 
of nanoparticles was already evident, and the amount of 
intracellular fluorescence progressively increased for up to 
24 hours at least (Figure 4E).
To exclude the possibility that T22-mediated  penetration 
of GFP was limited to a particular cell type, we also 
 evaluated the intracellular fluorescence in exposed CXCR4+ 
SW1417 cells, a human cell line used to generate a mice 
model of metastatic colorectal cancer for preclinical 
studies through orthotopic implantation.18 Again, strong 
penetration (Figure 5A) and perinuclear fluorescence 
labeling  (Figure 5B) were seen in this model, indicative 
of efficient penetration of the nanoparticles. No changes 
in cell morphology (which would have been indicative of 
toxicity) were observed  (Figures 4A and 5A), or when com-
pared with cells exposed to parental GFP-H6 (Figures 4A 
and 5C).  Furthermore, viability of T22-GFP-H6-exposed 
SW1417 cells remained unaffected up to 72 hours after 
exposure (Figure 5D), even when high protein concentrations 
were added. On the other hand, penetration of T22-GFP-H6 
was observed to be dose-dependent (Figure 5E) in both 
human HeLa and SW1417 cells, and efficiently inhibited 
by increasing amounts of SDF1α  (Figure 5F), the natural 
ligand of CXCR4.23 These data confirm the specificity of 
intracellular delivery driven by the T22 peptide.
Stability and architecture  
of T22-empowered GFP nanoparticles
The confocal microscopy analyses shown in Figures 4 and 5 
indicate that T22-GFP-H6 has a nanostructure, as has been 
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Figure 2 Biochemical characterization of protein constructs upon protein purification. 
Notes: Mass spectrometry of the purified constructs indicating the experimental molecular weight. The obtained N-terminal sequence is also shown, always coincident with 
the predicted sequence (Figure 1A). Protein integrity is also shown through Coomassie blue-stained sodium dodecyl sulfate polyacrylamide gel electrophoresis gels (Co) and 
by H6 immunodetection in Western blot (WB).
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Figure 3 Differential internalization of CXCR4 ligands. 
Notes: Internalization of T22-GFP-H6 and alternative constructs in HeLa cells, 
monitored by flow cytometry 24 hours after exposure.
Abbreviation: GFP, green fluorescent protein.
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previously demonstrated for the related construct, R9-GFP-H6.13 
Although precise characterization of these assemblies 
is beyond the scope of this study, we were interested in 
confirming that T22-GFP-H6 is organized in nanoparticle 
form and that T22 can achieve targeted internalization 
of large macromolecular complexes. If so, T22 would 
be of broad interest for the functionalization of other 
categories of nanoparticles (eg, nonproteins) in emerg-
ing medicine. First, we determined that the construct 
was highly stable in human serum (Figure 6A) and able 
to internalize target cells fully in the presence of fetal 
bovine serum (Figure 6B). These features are suggestive 
of proteolytic stability, tight architecture, and regular 
organization of T22-GFP-H6 building blocks, in contrast 
with the random particle size and morphologies observed 
during amorphous protein aggregation, even in the form of 
soluble aggregates.24–27 Indeed, the mean size of T22-GFP-
H6, measured by dynamic light scattering, was 13.45 nm 
(Figure 6C), a value fully compatible with images of these 
nanoparticles under transmission electron microscopy 
(Figure 6D) showing relatively monodispersed entities. 
To assess further the structural and functional stability of 
T22-empowered nanoparticles, we determined their size 
distribution after storage for one year at -80°C, and also at 
room temperature for an additional 24 hours, followed by 
one additional step of freezing and thawing. As observed 
(Figure 7A), no important variations in nanoparticle size 
were observed, in agreement with their high stability in 
human serum (Figure 6A). After 24 hours of incubation at 
room temperature, we observed a slight tendency for the 
nanoparticles to become more compact entities, although 
the reduction in size was very moderate (around 1 nm on 
average). These nanoparticles were indistinguishable from 
the original material in terms of their ability to internalize 
cultured cells (Figure 7B). All these data confirm that the 
presence of T22, as it occurs with the cationic peptide R9, 
imparts self-organizing properties to His-tagged GFP, that 
cannot form multimeric complexes on its own.13
Given that T22 is also highly cationic (note its primary 
sequence in Figure 1A), we wondered if this peptide could 
promote electrostatic interaction between monomers to 
achieve stable nanoparticulate entities. To explore this 
possibility, we generated a charge map of T22-GFP-H6 
(Figure 8A). The highly dipolar charge distribution of the 
multifunctional protein did indeed enable tight electrostatic 
contact between the charged sides of the GFP beta barrel 
and the consequent generation of regular oligomers. Two 
stable multimeric assemblies of T22-GFP-H6 monomers into 
approximately 13 nm nanoparticles are shown in Figure 8B, 
but alternative arrangements of the building blocks were 
also thermodynamically feasible (data not shown). Further 
structural analyses are in progress to elucidate the nature of 
the architectonic properties of T22, beyond those associated 
with its cell-targeting ability.
T22-mediated intracellular targeting  
in a model of metastatic colorectal cancer
The excellent in vitro performance of T22 in receptor-
 specif ic intracellular targeting and the architectonic 
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Figure 4 Differential internalization and intracellular trafficking of CXCR4 ligands. 
(A) Confocal images of HeLa cells exposed to differently tagged proteins for 24 hours. 
Nuclei are labeled in blue and cell membranes in red. Bar indicates 20 µm. (B) Detail 
of a HeLa cell exposed to T22-GFP-H6, showing the intracellular localization of 
nanostructured, fluorescent entities, in an isosurface representation within a three-
dimensional volumetric x-y-z data field. (C) Yellow spots in the cell membrane, 
marked with an arrow, indicate early endosomal localization of green fluorescent 
particles (merging of red and green signals). In the insets, details of endosome-
embedded fluorescent particles dissected by three-dimensional reconstruction. 
(D) Intracellular tracking of individual fluorescent particles monitored by confocal 
microscopy. (E) Time course monitoring of T22-GFP-H6 internalization in HeLa 
cells by flow cytometry.
Abbreviation: GFP, green fluorescent protein.
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Figure 5 Internalization of T22-GFP-H6 in SW1417 cells. (A) Isosurface representation of T22-GFP-H6-exposed SW1417 cells within a three-dimensional volumetric x-y-z 
data field. (B) The particulate nature of the protein and the perinuclear accumulation are clearly observed. (C) Isosurface representation of GFP-H6-exposed SW1417 cells 
showing lack of fluorescence. (D) MTT analysis of SW1417 cells exposed to different concentrations of T22-GFP-H6. As a control, we used determined viability of cells 
exposed to the storing buffer alone. Values are referred to cell viability of cultures not exposed to the buffer. (E) Dose-response curve of T22-GFP-H6 internalization in HeLa 
and SW1417 cells. Data adjusted to hyperbolic equations with r2 = 0.9620 for HeLa cells and r2 = 0.9978 for SW1417 cells (both P , 0.001). (F) Inhibition of T22-GFP-H6 
internalization in HeLa and SW1417 by increasing competitor/protein ratios of the natural CXCR4 ligand SDF1α. 
Notes: GFP-H6 and human GLA were included as negative controls. Asterisks indicate significant differences when comparing with any of the negative controls (P , 0.001).
Abbreviations: GFP, green fluorescent protein; GLA, α-galactosidase. 
robustness of T22-empowered nanoparticles encouraged 
us to proceed further with in vivo biodistribution analy-
ses in a CXCR4+ mouse model of metastatic colorectal 
cancer18 (Figure 9A). Upon tail vein administration, 
the green fluorescence in local tumors (Figure 9B) and 
metastatic foci (Figure 9C) was much more intense than 
the background levels observed in buffer-treated mice 
(Figures 9A and 10A). The fluorescent signal was dose-
dependent, peaked at 5 hours, and remained relatively 
stable for at least 24 hours  (Figure 10A). This temporal 
profile is again indicative that the nanoparticles have high 
in vivo stability for at least one day following administra-
tion. When analyzing other tissues, we observed fluorescent 
metastatic foci in the peritoneum and lymph nodes but not 
in healthy organs (Figure 9B and C,  Figure 10A and B), 
indicating tumor-specific targeting of the nanoparticles 
and accurate CXCR4-linked biodistribution. Finally, as in 
the cell cultures, we also observed cytosolic localization 
of T22-GFP-H6 by immunohistochemistry in both local 
tumor and metastatic foci (Figure 10C), demonstrating 
efficient cell internalization of the T22-functionalized 
constructs in vivo. No fever or other signs of toxicity were 
observed in any of the treated animals during the study 
(data not shown).
Discussion
Controlling cell targeting and penetrability of drugs and imag-
ing agents is a major issue in emerging medicine.  Successful 
identification of efficient intracellular targeting agents is 
expected to result in dramatic increases in drug stability and 
efficacy, as well as in significant reduction of toxicity and 
production costs. Given that the cell membrane is a major bio-
logical barrier for chemicals and particulate entities,28 identi-
fication of “Trojan horses” for selective intracellular delivery, 
ie, peptides or antibodies which selectively bind cell surface 
receptors and promote selective uptake of attached cargos,29 
is a major demand in preclinical and clinical research, espe-
cially in cancer chemotherapy. However, very few of these 
peptides prove to be suitable for internalization of macro-
molecular complexes or nanoparticles, and lack of targeting 
remains a major obstacle in the design of effective drugs and 
full development of nanomedicine.30 In cancer chemotherapy, 
incorporation of monoclonal antibodies as drug targeting 
agents has had limited benefit for patients because of poor 
tumor penetration31 and unexpectedly rapid development of 
chemoresistance.32 Also, generic use of antitumor antibodies 
for targeting is controversial because only 0.001%–0.01% of 
these localize to the target site upon administration.33 Despite 
the steady identification of tumor-homing peptides,34,35 tags 
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for receptor-dependent internalization of macromolecular 
complexes and  nanoparticles are still unavailable.36 In this 
study, we identified that T22, a short amino acid segment 
(Figure 1A), is an unusually strong agent for intracellular 
 targeting in CXCR4+ cells, the  selectivity, stability and effi-
cacy of penetration of which have been fully demonstrated 
in cell culture (Figures 3–5) and in vivo  (Figures 9 and 10). 
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Figure 6 Characterization of T22-empowered nanoparticles. (A) Remaining 
fluorescence during incubation of T22-GFP-H6 in human serum. In the inset, 
integrity of T22-GFP-H6 monomers monitored by Western blot. (B) Internalization 
of T22-GFP-H6 in HeLa cells in the presence of 10% fetal calf serum, monitored 
by the number of fluorescent cells. (C) Dynamic light scattering size analysis 
of T22-GFP-H6 nanoparticles in NaCO3H buffer. (D) Transmission electron 
microscopy of T22-GFP-H6 nanoparticles.
Abbreviation: GFP, green fluorescent protein.
In addition, we produced T22 at high yields in a recombi-
nant form as a domain of a highly stable modular protein 
 (Figure 2), demonstrating lack of toxicity of this peptide in 
E. coli and pointing to the feasibility of production of further 
(improved or adapted) engineered versions.
Interestingly, T22 had been previously identified as a 
CXCR4 ligand and explored in the context of antiretroviral 
therapies,37 because CXCR4 is a coreceptor for HIV and 
T22 inhibits viral attachment. However, the ability of T22 
to penetrate cells was not suspected. Importantly, internal-
ization of T22 does not depend on mere interaction with 
CXCR4, because other ligands tested in this study failed 
to promote efficient uptake (Figures 3 and 4), even show-
ing that affinity for the receptor was higher than for T22.10 
 Dissociation between affinity for the receptor and endocytosis 
might account for the limited penetrability and poor uptake 
of antibody-empowered drugs.31,38 Other CXCR4 ligands 
previously investigated for targeted drug delivery showed 
very low or null penetration, even revealing themselves 
as agonists of CXCR4 and stimulating cell division.39 In 
contrast, in our hands, T22-exposed cells never showed 
significant proliferation compared with controls (data not 
shown). The efficient endosomal escape of the constructs 
generated might be due to the proton-sponge activity of the 
accompanying polyhistidines that, while useful for one-step 
protein purification, act also as a proton sponge, permitting 
endosomal disruption and delivery of the functionalized 
materials into the cytoplasm.22
On the other hand, when tested in an in vivo animal 
model of colorectal cancer, in which CXCR4+ cells were 
associated with aggressiveness, T22-empowered nanopar-
ticles selectively localized not only in the primary tumor but 
also in metastatic foci (Figures 9C, 10B and C) confirming 
good stability of the protein-only nanoparticles generated 
in this study and suggesting that these nanoparticles might 
eventually be able to be attached to drugs to control tumor 
spread. This would be especially promising if used in the 
early stages of disease, because current treatment strategies 
for colorectal cancer are targeted to the primary tumor rather 
than to disseminated disease.40 Moreover, achieving higher 
intracellular concentrations of anticancer agents is expected 
to lead to a better antitumor effect, given that most of the 
chemotherapeutic agents used have a steep dose-response 
relationship.41 In the same context, precise targeting of 
imaging agents to metastatic foci would create additional 
diagnostic strategies.
Finally, T22 was able to impart self-organizing properties 
to GFP-H6, as has been previously shown for another cationic 
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Figure 8 Molecular modeling of T22-GFP-H6 monomers and nanoparticles. 
(A) Electrostatic field of the T22-GFP-H6 building monomer (cationic in blue and 
anionic in red). (B) Potential organization of T22-GFP-H6 as pentamers of 11.1 nm 
(left) and as octamers of 13.3 nm (right), in which the intervention of T22 assists the 
electrostatic self-assembling of the multimeric protein complex.
Abbreviation: GFP, green fluorescent protein.
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Figure 7 Stability of T22-GFP-H6 nanoparticles. (A) Size distribution of T22-GFP-H6 nanoparticles after one year of storage at -80°C. The same sample was further 
incubated at room temperature for 24 hours, submitted to one additional freezing and thawing step and analyzed. (B) These samples were tested for their ability to internalize 
SW1417, showing uptake images comparable with those shown in Figures 4 and 5.
Abbreviations: GFP, green fluorescent protein; RT, room temperature.
stretch, namely the receptor-independent cell-penetrating pep-
tide, R9.13 The resulting building blocks, probably establishing 
electrostatic contact due to their dipolar nature (Figure 8), form 
relatively monodispersed protein-only nanoparticles about 
13 nm in size (Figure 6), with proteolytic stability in human 
serum (Figure 6A) on systemic administration  (Figures 9 
and 10) and remaining assembled and fully functional under 
different storage conditions (Figure 7).  Interestingly, T22-
empowered building blocks are highly fluorescent (22.8 fluo-
rescence units/µg), indicative of a poor impact of the peptide on 
GFP. V1-GFP-H6 shows slightly lower fluorescent emission 
(12.4 fluorescence units/µg), being sufficiently high to monitor 
cell penetration, indicative of the conformational constraints 
imposed by the peptide on the building block.
Although the nanoscale architectonic properties imparted 
by T22 to the holding building block are secondary in terms 
of their CXCR4-dependent intracellular targeting ability, they 
warrant further investigation as architectonic tags for con-
struction of protein-only nanoparticles.42,43 Self-assembling 
peptides, presently under intense investigation in diverse 
nanomedical applications,44–47 base their organizing proper-
ties on amyloid-like cross-molecular interactions, and when 
produced in “cell factories” such as E. coli, tend to aggregate 
as amorphous protein deposits.48 CXCR4 is an important 
cell surface marker in HIV infection,5 metastatic colorectal 
cancer,8,9 and other neoplasms,6 so incorporation of T22 as 
a targeting agent offers many opportunities for functional-
ization of drugs and nanoparticles for intracellular delivery, 
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Figure 10 Accumulation of T22-empowered nanoparticles in colorectal cancer metastatic foci. Enhanced green fluorescence associated with nanoparticle accumulation 
in local tumors (A) and peritoneal metastases (B) in experimental mice, as compared with buffer-treated controls. (C) Anti-His tag inmunostaining showing cytosolic 
localization of T22-GFP-H6 in local tumor tissue and peritoneal metastases in mice injected with T22-NP, which was absent in control animals injected with buffer.
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Figure 9 Biodistribution of T22-empowered nanoparticles in an animal model of colorectal cancer. (A) Nude mouse bearing a local tumor (black asterisk), mesenteric lymph 
node (black arrow), and peritoneal metastases (empty arrow) after microinjecting 2 × 106 SW1417 human colorectal cancer cells into the cecal wall. The local tumor and 
mesenteric lymph node metastases overexpress CXCR4 in this model, as assessed by immunohistochemistry. (B) Selective biodistribution of T22-GFP-H6 in local tumor 
tissues 5, 24, or 48 hours after intravenous administration of 500 µg or 20 µg of nanoparticles as measured ex vivo. Fluorescence was undetectable in tumors from buffer-
treated animals. (C) Accumulation of nanoparticles in peritoneal and lymph node metastases. No fluorescence was observed in any normal (liver, kidney, lung, heart) tissue, 
except for the biliary vesicle which showed fluorescence both in control and experimental animals.
Abbreviation: GFP, green fluorescent protein.
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especially for disorders in which CXCR4 expression plays 
a pathophysiological role, including cancer, inflammation, 
autoimmunity, and ischemic lesions.4
Conclusion
The peptide T22, a known ligand of CXCR4, has been shown 
to be an unusually powerful tag for intracellular targeting in 
CXCR4+ cells, both in cell culture and in vivo. T22 is able 
to mediate the internalization of self-assembling protein-only 
nanoparticles 13 nm in mean diameter, keeping the stability 
and fluorescence emission of GFP-based building blocks. 
Rapid endosomal uptake and perinuclear accumulation of 
T22-empowered nanoparticles without cytotoxicity offer a 
wide spectrum of diagnostic and therapeutic opportunities 
for use of T22 in emerging nanomedicine to treat CXCR4-
linked diseases, for which intracellular targeting agents are 
currently missing.
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